Abstract
BackgroundPatients with end stage liver disease are characteristically malnourished which is associated with poor outcome. Formulas enriched with arginine, ω-3 fatty acids, and nucleotides, "immunonutrients", potentially improve their nutritional status. This study is designed to evaluate the clinical outcome of long-term "immunonutrition" of patients with end-stage liver disease while on the waiting list for liver transplantation.Methods/designA randomized controlled double blind multi-center clinical trial with two parallel groups comprising a total of 142 newly registered patients for primary liver transplantation has been designed to assess the safety and efficacy of the long-term administration of ORAL IMPACT®, an "immunonutrient" formula, while waiting for a graft. Patients will be enrolled the day of registration on the waiting list for liver transplantation. Study ends on the day of transplantation. Primary endpoints include improved patients' nutritional and physiological status, as measured by mid-arm muscle area, triceps skin fold thickness, grip strength, and fatigue score, as well as patients' health related quality of life. Furthermore, patients will be followed for 12 postoperative weeks to evaluate anabolic recovery after transplantation as shown by reduced post-transplant mechanical ventilation, hospital stay, wound healing, infectious morbidities (pneumonia, intraabdominal abscess, sepsis, line sepsis, wound infection, and urinary tract infection), acute and chronic rejection, and mortality.DiscussionFormulas enriched with arginine, ω-3 fatty acids, and nucleotides have been proven to be beneficial in reducing postoperative infectious complications and length of hospital stay among the patients undergoing elective gastrointestinal surgery. Possible mechanisms include downregulation of the inflammatory responses to surgery and immune modulation rather than a sole nutritional effect.Trial registrationClinicalTrials.gov NCT00495859
Highlights
Patients with end stage liver disease are characteristically malnourished which is associated with poor outcome
Immunonutrition Patients with end-stage liver disease (ESLD) characteristically suffer from protein-energy malnutrition (PEM) and hypermetabolism due to abnormal nutrient and caloric intake, decreased intestinal absorption, and metabolic disturbances, which is associated with poor outcome including poor perceived health-related quality of life (HRQL) [1,2] and unsatisfactory postoperative course, i.e., prolonged intensive care unit and total hospital stay, prolonged mechanical ventilation, and increased morbidities and mortality [3,4]
Ω-3 fatty acids, and nucleotides have been proven to be beneficial in reducing postoperative infectious complications and length of hospital stay among the patients undergoing elective gastrointestinal surgery, especially in those who are malnourished preoperatively [21]
Summary
Patients with end stage liver disease are characteristically malnourished which is associated with poor outcome. Immunonutrition Patients with end-stage liver disease (ESLD) characteristically suffer from protein-energy malnutrition (PEM) and hypermetabolism due to abnormal nutrient and caloric intake, decreased intestinal absorption, and metabolic disturbances, which is associated with poor outcome including poor perceived health-related quality of life (HRQL) [1,2] and unsatisfactory postoperative course, i.e., prolonged intensive care unit and total hospital stay, prolonged mechanical ventilation, and increased morbidities and mortality [3,4]. Ω-3 fatty acids, and nucleotides (immune enhancing diets or the so-called "immunonutrients" – which are designed to modulate a patient's immune response and can augment basic nutritional repletion) have been proven to be beneficial in reducing postoperative infectious complications and length of hospital stay among the patients undergoing elective gastrointestinal surgery, especially in those who are malnourished preoperatively [21]. Possible mechanisms include downregulation of the inflammatory responses to surgery and immune modulation rather than a sole nutritional effect
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have